At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy, Carboplatin, and 4 other interventions for Stage II Non-Small Cell Lung Cancer and 2 related conditions. Completed, enrolled 23 participants across 3 sites.
Detailed Summary
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab together with paclitaxel, carboplatin, and radiation therapy may kill more tumor cells.
Study Details
Timeline
Interventions
Undergo 3D-CRT or IMRT
Given IV
Undergo 3D-CRT or IMRT
Correlative studies
Given IV
Given IV